Skip to Content

Promising Results from EHA23: Gilteritinib as Posttransplant Maintenance Therapy for FLT3-ITD AML Patients

New data presented at EHA23 indicates the potential of gilteritinib in eradicating minimal residual disease and its implications for improving outcomes in high-risk AML patients.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top